FiercePharma  Apr 5  Comment 
Sanofi is out another potential buyer for its European generics business with the exit of expansion-minded Indian drugmaker Torrent Pharma from deal talks, according to a report.
FiercePharma  Apr 3  Comment 
Sanofi's new atopic dermatitis launch Dupixent hit a roadblock with the influential cost-effectiveness gatekeepers in England. NICE figures the drug works—and offers an option for patients who really need one—but isn't sure it's worth the price.
MedPage Today  Apr 2  Comment 
(MedPage Today) -- Docetaxel, abiraterone plus ADT for non-CRPC
FierceBiotech  Mar 26  Comment 
A phase 2 trial of Ablynx’s vobarilizumab in systemic lupus erythematosus has missed its primary endpoint. The setback tarnishes one of the drugs Sanofi is set to acquire through its $4.8 billion takeover of Ablynx.
FiercePharma  Mar 22  Comment 
As Sanofi presses ahead with the sale of its European generics unit, a private equity firm has reportedly bowed out over price. Analysts have said the business could fetch €2 billion for the French drugmaker, which is streamlining to focus on...

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki